AGM/EGMApr 30, 2026, 04:40 PM
IMA Annual Meeting: 2025 Equity Plan Share Increase by 850,000
AI Summary
ImageneBio, Inc. announced its Annual Meeting of Stockholders will be held virtually on June 16, 2026, at 9:00 a.m. Eastern Time. Stockholders will vote on the election of two Class II directors, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026, and the approval of an amendment to the 2025 Equity Incentive Plan to increase authorized shares by 850,000. The company was formed in July 2025 through a merger between Ikena Oncology, Inc. and Inmagene Biopharmaceuticals, which also involved a 1-for-12 reverse stock split and a $75.0 million PIPE financing.
Key Highlights
- Annual Meeting to be held virtually on June 16, 2026, at 9:00 a.m. Eastern Time.
- Stockholders of record as of April 28, 2026, are entitled to vote.
- Proposals include electing two Class II directors to serve until the 2029 Annual Meeting.
- Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year 2026.
- Approval of 2025 Equity Incentive Plan amendment to increase authorized shares by 850,000.
- ImageneBio, Inc. was formed from the merger of Ikena Oncology, Inc. and Inmagene Biopharmaceuticals in July 2025.
- Ikena Oncology, Inc. effected a 1-for-12 reverse stock split prior to the merger.
- A 2025 PIPE Financing raised approximately $75.0 million by issuing 2,508,337 shares at $29.90 per share.
Price Impact
More from IMA